Net Loss per Common Share (Tables)

9 Months Ended

Sep. 30, 2025

Earnings Per Share [Abstract]

Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders

The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:


	September 30,
	2025				2024*
Stock options outstanding		12,580,264				6,964,592
Non-vested and unsettled restricted stock units		1,800,089				2,987,279
Shares reserved for future issuance		5,134,310				1,547,455
Apexigen replacement warrants		1,003,191				1,003,191
Employee stock purchase plan		653,777				589,004
Total		21,171,631				13,091,521

*Pre-Funded Warrant Shares of 1,611,215 shares are included in the computation of basic and diluted net loss per common share for the three and nine months ended September 30, 2024 as the Pre-Funded Warrants were issuable for nominal consideration.